Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab versus placebo for ulcerative pyoderma gangrenosum requiring systemic therapy
2024-514306-31-00Phase 3Authorised
- Sponsor
- LEO Pharma
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in pyoderma gangrenosum (PG) comparing Spesolimab with Placebo comparator (2 arms). Primary endpoint: Complete closure of target ulcer by Week 26. Planned start Feb 2025; status: authorised.
02
Drugs
spesolimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on 2024-514306-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514306-31-00.